Saint Louis University
St Louis, Missouri, 63110, United States
NCT Number: NCT01693666
Gaining too much weight in pregnancy is associated with adverse pregnancy complications and can have a long-term impact on maternal and offspring health, including increased risk for obesity and metabolic disease. Preventing excessive gestational weight gain could reduce adverse pregnancy outcomes and improve long-term health of mothers and offspring. Thirty obese (BMI ≥30) pregnant women will be recruited for this pilot study and randomly assigned to the Lifestyle Intervention ForEver (LIFE) program or routine care (RC). Participants will be enrolled before 18 weeks gestation and will be followed until 12 weeks after delivery. Women in the LIFE program will be given guidance on healthy eating and exercise at their regularly scheduled obstetric visits. To increase adherence to the program, a contingency management (CM) intervention offering incentives will be used to establish and maintain healthy nutrition and physical activity habits, working towards the goal of restricted weight gain (± 10lb) during their pregnancy. Three study testing visits will be scheduled for all participants: at study entry, 34-36 weeks gestation, and 12 weeks after delivering. Primary outcomes include adherence to the LIFE program, weight change in pregnancy and postpartum, and objective measures of maternal and offspring health.
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Not applicable
St Louis, Missouri, 63110, United States
The ultimate goal of this research is to examine the impact of a healthy lifestyle intervention, targeting weight gain restriction during pregnancy in obese women (BMI≥30kg/m2), on maternal and fetal outcomes.
The overarching research program has 3 main objectives:
The experimental hypotheses to be tested are that participation in the LIFE intervention in obese pregnant women will prevent excessive weight gain and/or achieve weight maintenance (± 10 lb) during pregnancy and will result in 7-10% weight loss at 12 weeks postpartum. Secondly, we hypothesize that participation in the LIFE intervention in obese pregnant women will be associated with improved aerobic capacity, reduced incidence of obstetric complications and reduced rates of LGA as a result of beneficial alterations to metabolic intrauterine environment for fetal growth.
With regard to this IRB application, we will be conducting a pilot and feasibility trial to address the following specific aims:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
i. Drug or alcohol abuse ii. Presence of any unstable psychiatric disorder iii. Plans to move away from the geographical area within the next nine months iv. Other medical or behavioral factors that, in the judgement of the supervising physician, may interfere with their ability to take part in a lifestyle intervention program during pregnancy.
Time frame: Approx. 20-25 weeks
Maternal weight (lb) will be measured at program entry and at the time of delivery to determine weight gain during the study period.
Pre-pregnancy body weight will be self-reported and used to estimate total gestational weight gain (lb).
Time frame: 16-21 weeks
Changes in lean and fat mass will be examined at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum
Time frame: 16-21 weeks
Peak aerobic capacity will be examined via a standard maximal oxygen consumption (VO2max) test performed on a stationary cycle ergometer at study entry, in late pregnancy (34-36 weeks gestation), and at 12 weeks postpartum
Time frame: 16-21 weeks
A fasted blood sample will be collected at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum to examine changes in lipid profile and adipokines (TNF-alpha, leptin). Fasting glucose, insulin and C-peptide will also be measured and entered into the homeostatic model (HOMA) to estimate changes in insulin sensitivity and beta cell function during the study period.
Time frame: 1-25 weeks
Parameters examined will include:
Time frame: 16-21 weeks
Dietary intake will be examined at study entry (15-18 weeks gestation), in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum.
Time frame: 16-21 weeks
Psychometric outcomes examined at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum include:
Time frame: 10-25 weeks
Fetal growth and abdominal circumference will be examined by fetal ultrasound at approximately 28-30, 34-36 and 38-40 weeks gestation and/or as part of routine care after 28 weeks gestation.
Time frame: Within 48 hours of birth
Between group comparisons of birth size will include birth weight (g), crown-heel length (mm), head circumference (mm), body mass index (kg/m2), ponderal index. Population-specific standard deviation (SD) scores will be calculated and the incidence of small for gestational age, appropriate for gestational age and large for gestational age will be compared between groups.
Time frame: Within 48 hours of birth
Neonatal lean and fat mass (g) will be calculated based on anthropometric measurements performed within 48 hours after birth
Time frame: 20-25 weeks
Concentrations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-1, IGF binding protein-3, glucose, insulin, leptin and triglyceride will be examined from cord blood samples taken at the time of delivery.
Time frame: 32-37 weeks
The following pilot and feasibility outcomes will be assessed:
Time frame: 12 weeks
Maternal weight (lb) will be measured at 6 & 12 weeks postpartum and compared to delivery weight (lb) to determine postpartum weight retention.
Time frame: 16-21 weeks
Physical activity levels will be examined at study entry (15-18 weeks gestation), in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum.
Time frame: 12 weeks
Between group comparisons of body weight (g), length (mm), head circumference (mm), body mass index (kg/m2), and ponderal index. Population-specific SD scores will be calculated and compared between groups.
Time frame: 12 weeks
Infant lean and fat mass (g) will be calculated based on anthropometric measurements performed at 12 weeks of age.
St. Louis University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01768793
Body Weight, Body Weight Changes
St Louis, Missouri, United States
View Trial DetailsNCT02701426
Behavior, Body Weight
Lille, France
View Trial DetailsNCT02142452
Body Weight, Body Weight Changes
Stanford, California, United States
View Trial DetailsNCT02574767
Body Weight, Body Weight Changes
Santiago, Chile
View Trial Details